Total Payments
$5,356
2024 Payments
$3,980
Companies
3
Transactions
6
Medicare Patients
1,515
Medicare Billing
$303,449

Payment Breakdown by Category

Research$3,980 (74.3%)
Travel$944.39 (17.6%)
Food & Beverage$418.76 (7.8%)
Education$11.92 (0.2%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $3,980 2 74.3%
Travel and Lodging $944.39 2 17.6%
Food and Beverage $418.76 1 7.8%
Education $11.92 1 0.2%

Payments by Type

Research
$3,980
2 transactions
General
$1,375
4 transactions

Top Paying Companies

Company Total Records Latest Year
Eli Lilly and Company $3,980 2 $0 (2024)
Roche Products Limited $1,363 3 $0 (2018)
Gilead Sciences, Inc. $11.92 1 $0 (2021)

Payment History by Year

Year Amount Transactions Top Company
2024 $3,980 2 Eli Lilly and Company ($3,980)
2021 $11.92 1 Gilead Sciences, Inc. ($11.92)
2018 $1,363 3 Roche Products Limited ($1,363)

All Payment Transactions

6 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
09/24/2024 Eli Lilly and Company Cash or cash equivalent $3,946.00 Research
Study: EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE
08/23/2024 Eli Lilly and Company In-kind items and services $34.45 Research
Study: EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE
06/01/2021 Gilead Sciences, Inc. Education In-kind items and services $11.92 General
05/09/2018 Roche Products Limited TECENTRIQ (Biological) Travel and Lodging In-kind items and services $616.87 General
Category: BioOncology
05/09/2018 Roche Products Limited TECENTRIQ (Biological) Food and Beverage In-kind items and services $418.76 General
Category: BioOncology
05/09/2018 Roche Products Limited TECENTRIQ (Biological) Travel and Lodging In-kind items and services $327.52 General
Category: BioOncology

Research Studies & Clinical Trials

Study Name Company Amount Records
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE Eli Lilly and Company $3,980 2

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 6 335 606 $457,668 $74,570
2022 7 394 627 $476,310 $84,718
2021 8 400 624 $346,569 $82,069
2020 8 386 596 $307,765 $62,091
Total Patients
1,515
Total Services
2,453
Medicare Billing
$303,449
Procedure Codes
29

All Medicare Procedures & Services

29 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 148 291 $200,499 $31,797 15.9%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2023 46 154 $150,766 $24,749 16.4%
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes Facility 2023 45 45 $39,555 $7,121 18.0%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2023 57 68 $33,592 $5,144 15.3%
99205 New patient office or other outpatient visit, 60-74 minutes Office 2023 20 20 $24,240 $3,737 15.4%
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes Facility 2023 19 28 $9,016 $2,023 22.4%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 137 256 $176,384 $29,498 16.7%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2022 49 149 $145,871 $25,542 17.5%
99223 Initial hospital inpatient care per day, typically 70 minutes Facility 2022 64 65 $57,135 $12,142 21.3%
99205 New patient office or other outpatient visit, 60-74 minutes Office 2022 35 35 $42,420 $7,538 17.8%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2022 58 66 $32,604 $5,429 16.7%
99233 Follow-up hospital inpatient care per day, typically 35 minutes Facility 2022 23 28 $12,880 $2,695 20.9%
99232 Follow-up hospital inpatient care per day, typically 25 minutes Facility 2022 28 28 $9,016 $1,875 20.8%
99215 Established patient outpatient visit, total time 40-54 minutes Office 2021 45 158 $101,278 $26,347 26.0%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 143 218 $103,458 $25,779 24.9%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2021 71 73 $64,167 $13,708 21.4%
99205 New patient outpatient visit, total time 60-74 minutes Office 2021 22 22 $20,218 $4,797 23.7%
99213 Established patient outpatient visit, total time 20-29 minutes Office 2021 49 54 $20,682 $3,949 19.1%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2021 36 58 $18,676 $3,838 20.6%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 22 27 $12,420 $2,503 20.2%
99442 Physician telephone patient service, 11-20 minutes of medical discussion Office 2021 12 14 $5,670 $1,148 20.2%
99214 Established patient office or other outpatient, visit typically 25 minutes Office 2020 152 233 $110,675 $21,613 19.5%
99215 Established patient office or other outpatient, visit typically 40 minutes Office 2020 52 130 $83,330 $16,344 19.6%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2020 43 44 $38,676 $8,489 21.9%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2020 53 90 $28,980 $6,158 21.2%

About Dr. Ruby Sharma, M.D

Dr. Ruby Sharma, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in New Hyde Park, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2007. The National Provider Identifier (NPI) number assigned to this provider is 1750589701.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ruby Sharma, M.D has received a total of $5,356 in payments from pharmaceutical and medical device companies, with $3,980 received in 2024. These payments were reported across 6 transactions from 3 companies. The most common payment nature is "" ($3,980).

As a Medicare-enrolled provider, Sharma has provided services to 1,515 Medicare beneficiaries, totaling 2,453 services with total Medicare billing of $303,449. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.

Practice Information

Products in Payments

  • TECENTRIQ (Biological) $1,363

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Student in an Organized Health Care Education/Training Program Doctors in New Hyde Park